share_log
Benzinga ·  May 7 07:15
Theriva Biologics Reports $18.3M In Cash For Q1 2024, Which Is Expected To Provide Runway Into The First Quarter Of 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment